MMV183

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for use in severe malaria
MoA
  • Inhibition of acetylCoA synthetase (acetylCS)
  • No pre-existing resistance, no resistance in vitro
Key features
  • Novel mechanism of action
  • Blood stage P. falciparum infection & blocks transmission
  • Predicted human efficacious dose = 100 mg single dose
  • High solubility and good overall physical properties
Challenges
  • Safety (absence of mechanism-based toxicity)
Status
  • Preclinical development
Next milestone
  • GLP toxicology and safety pharmacology
  • Optimization of synthesis route, CMC and formulation
Previously
  • From a discovery collaboration with TropIQ
MMV Project Director
  • Ilaria Di Resta